9:30-9:35

Opening Remark

Masayuki Yamamoto

9:35-11:05

1) Keynote Lectures

Chairpersons: Masayuki Yamamoto & Thomas W. Kensler
-9:35-10:20 (45 min) Masayuki Yamamoto
Sixth Environmental Stress Symposium on the KEAP1-NRF2 System Regulating the Molecular Basis of Oxidative Stress Response and Its Perturbation
-10:20-11:05 (45 min) Thomas W. Kensler
How Important is NRF2 for the Pharmacodynamic Action of “NRF2 Inducers"?

Co-sponsored by Chugai Pharmaceutical Co., Ltd.

11:05-11:25 Break

11:25-12:25

2) Session: Molecular Mechanisms of the KEAP1-NRF2 System Function

Chairperson: Donna D. Zhang
-11:25-11:55 (30 min) Hozumi Motohashi
NRF2 Buddy for Transcriptional Activation
-11:55-12:25 (30 min) Michael B. Major
Proximity Proteomic Analysis Reveals Mechanisms of KEAP1 Inactivation by Cysteine Modification and New Connections for NRF2 in Parkinson's Disease

12:25-13:55 Lunch time & Poster Discussion (ODD number)

13:55-16:05

2) Session: Molecular Mechanisms of the KEAP1-NRF2 System Function

Chairperson: Donna D. Zhang
-13:55-14:35 (40 min) Albena T. Dinkova-Kostova
Nrf2 depletion in the context of Keap1 loss-of-function leads to mitolysosome accumulation
-14:35-15:05 (30 min) Ken Itoh
Cross-talk of GCN1-GCN2 branch of ISR and Nrf2 pathway in environmental stress response
-15:05-15:35 (30 min) Elias S.J. Arnér
Selenium in control of ferroptosis – potential roles and cross-talk between glutathione peroxidases and thioredoxin reductases
-15:35-16:05 (30 min) Takafumi Suzuki
Molecular Basis of Stress Response by the KEAP1-NRF2 System

16:05-16:25 Break

16:25-18:15

2) Session: Molecular Mechanisms of the KEAP1-NRF2 System Function

Chairperson: Ken Itoh
-16:25-16:55 (30 min) Donna D. Zhang
From Antioxidant Defense to Iron Homeostasis: NRF2's Multifaceted Guard Against Ferroptosis
-16:55-17:15 (20 min) Youngtae Jeong
Keap1-Nrf2 pathway in the cancer therapeutic resistance and anti-tumor immunity
-17:15-17:35 (20 min) John D. Hayes
Inhibition of liver fibrosis by Nrf2: antagonism of Nrf2 by TGF-beta
-17:35-17:55 (20 min) Nobunao Wakabayashi
Forced Hepatic Expression of NRF2 or NQO1 Alleviates Hepatic Lipid Accumulation and Hepatocellular Damage in a Lipodystrophy Mouse Model
-17:55-18:15 (20 min)Tetsuro Ishii
Mechanisms underlying Nrf2 activation by non-lethal levels of hydrogen peroxide: roles of glutathione sensor neutral sphingomyelinase2, p38 and ERK MAP kinases and prolyl cis/trans isomerase Pin1

18:30- Welcome Reception @Cafeteria

9:00-11:00

3) Session: The KEAP1-NRF2 System and Cancers

Chairperson: Hozumi Motohashi
-9:00-9:30 (30 min) Anna-Liisa Levonen
NRF2 and Cancer Immunity
-9:30-10:00 (30 min) Young-Joon Surh
Pseudohypoxic stabilization of HIF-1α through direct interaction with NRF2 in hepatocellular carcinoma
-10:00-10:30 (30 min) Gina M. DeNicola
Distinct Nrf2 signaling thresholds mediate lung tumor initiation and progression
-10:30-11:00 (30 min) Kate D. Sutherland
Identifying novel vulnerabilities to sensitise KEAP1 mutant lung adenocarcinoma to T cell mediated killing

11:00-11:20 Break

11:20-12:50

3) Session: The KEAP1-NRF2 System and Cancers

Chairperson: Anna-Liisa Leveon
-11:20-11:40 (20 min) Fumiki Katsuoka
Functional Characterization of CNC-sMAF Heterodimers by the Tethered Dimer Rescue System
-11:40-12:00 (20 min) Liam Baird
Immunoediting of KEAP1-NRF2 mutant tumours is required to circumvent NRF2-mediated immune surveillance
-12:00-12:30 (30 min) Thales Papagiannakopoulos
Uncovering Metabolic Bottlenecks in KEAP1-mutant Lung Cancer
-12:30-12:50 (20 min) Akira Kobayashi
NRF3: The NRF2-Related Transcription Factor Responding to Arginine Depletion in Cancer

12:50-14:20 Lunch time & Poster Discussion (EVEN number)

14:20-15:40

4) Session: The KEAP1-NRF2 System and Diseases

Chairperson: Keiko Taguchi
-14:20-14:50 (30 min) Jingbo Pi
NRF1 and NRF2 coordinate osteoclastogenesis and bone remodeling
-14:50-15:20 (30 min) Gerasimos Sykiotis
New roles of Keap1/Nrf2 signaling in thyroid gland function and thyroid pathophysiology
-15:20-15:40 (20 min) Mi-Kyoung Kwak
NRF2 and HIF-2α-induced cancer stem cell phenotypes in chronic hypoxic conditions

15:40-16:00 Break

16:00-17:50

4) Session: The KEAP1-NRF2 System and Diseases

Chairperson: John D. Hayes
-16:00-16:30 (30 min) Ian Copple
Pharmacology & toxicology of Nrf2 in the liver
-16:30-16:50 (20 min) Ana I. Rojo
Defining the role of the NRF2 transcription factor in synaptic maintenance in Alzheimer’s disease
-16:50-17:10 (20 min) Ioannis Trougakos
NRF2 in stress, ageing and disease
-17:10-17:30 (20 min) Florian A. Karreth
The small MAF transcription factor MAFG is a potent driver of melanoma
-17:30-17:50 (20 min) Masaki Hoshino
The efficacy of the novel NRF2 activator CH0924 for acute kidney injury

18:15- Round-Table Discussion @ ToMMo atrium

8:40-10:10

5) Session: The KEAP1-NRF2 System and Drug Development

Chairperson: Antonio Cuadrado
-8:40-9:20 (40 min) Karen T. Liby
Developing therapies to target NRF2
Co-sponsored by Kyowa Kirin Co.,Ltd. -9:20-9:50 (30 min) Terry W. Moore
Non-Electrophilic NRF2 Activators Promote Wound Healing in Human Keratinocytes and Diabetic Mice and Demonstrate Selective Downstream Gene Targeting
-9:50-10:10 (20 min) Akihito Otsuki
ibSLS database: an integrated database for the exploration of environmental stress response during space flight

10:10-10:30 Break

10:30-12:00

5) Session: The KEAP1-NRF2 System and Drug Development

Chairperson: Albena T. Dinkova-Kostova
-10:30-10:45 (15 min) Anqi Zhang
Nrf2 Activation Improves Experimental Rheumatoid Arthritis
-10:45-11:00 (15 min) Sharadha Dayalan Naidu
Pharmacologic and genetic activation of Nrf2 confers anti-fibrotic effects
-11:00-11:15 (15 min) Aikseng Ooi
Sexual dimorphism of NRF2 target gene modulation
-11:15-11:30 (15 min) Xiaoxin Luke Chen
Small Molecule Screen Identifies Pyrimethamine as an Inhibitor of NRF2-driven Esophageal Hyperplasia
-11:30-12:00 (30 min) Antonio Cuadrado
Targeting the NRF2/beta-TrCP axis in liver disease

12:00-12:15

Closing Remark
Masayuki Yamamoto

12:15-13:30 Lunch

13:30-15:00

Public Lecture "Space & Health" >> see more details

16:00-

Excursion >> see more details